Clinical Trial Update: Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial to assess different doses of UK-369,003 in men with overactive bladder; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• UK-369,003 (UK-369,003)

Snippet

Sponsor: Pfizer | Conditions: Urinary Bladder, Overactive | Phase 2 | Status: COMPLETED